Visikol
Visikol is a contract research services company specializing in advanced tissue imaging and cell culture assays to accelerate drug discovery and development. Founded in 2016 and acquired by BICO in 2021, Visikol serves the top 20 pharmaceutical companies and over 1,000 research labs worldwide. The company offers end-to-end services including 3D tissue imaging, multiplex tissue imaging, digital pathology, high content imaging, and 2D/3D cell culture assays. Visikol differentiates itself with patented tissue imaging and analysis technologies, AI-enhanced digital pathology, and custom research plans, positioning itself as an extension of clients' R&D teams. It also sells tissue clearing reagents, kits, and the HUREL® Micro Liver portfolio of primary hepatocyte models, supporting pharmaceutical and biotech clients globally.
Visikol
Visikol is a contract research services company specializing in advanced tissue imaging and cell culture assays to accelerate drug discovery and development. Founded in 2016 and acquired by BICO in 2021, Visikol serves the top 20 pharmaceutical companies and over 1,000 research labs worldwide. The company offers end-to-end services including 3D tissue imaging, multiplex tissue imaging, digital pathology, high content imaging, and 2D/3D cell culture assays. Visikol differentiates itself with patented tissue imaging and analysis technologies, AI-enhanced digital pathology, and custom research plans, positioning itself as an extension of clients' R&D teams. It also sells tissue clearing reagents, kits, and the HUREL® Micro Liver portfolio of primary hepatocyte models, supporting pharmaceutical and biotech clients globally.
TL;DR
What they do: CRO offering advanced tissue imaging, image analysis, digital pathology, and 2D/3D cell-culture assay services plus reagents and hepatocyte models
Founded / origins: Originated from Rutgers University research (tissue-clearing developed 2012); incorporated as a CRO ~2016
Exit / ownership: Acquired by CELLINK (BICO) in 2021
Customer reach: Serves top 20 pharmaceutical companies and 1,000+ research labs
Company Overview
Problem Domain
Drug discovery and preclinical research workflows requiring advanced tissue imaging, quantitative image analysis, and physiologically relevant in vitro models.
Founded
2016
Industry
Contract research services / biotechnology
Tech Stack
Funding Track Record
4750000.00
Investor Signal
“Acquired by CELLINK (BICO) in 2021; prior investors include grants from the U.S. National Institutes of Health (NIH) and the National Science Foundation (NSF)”